Analysis Of Risk Factors For Nonalcoholic Fatty-Liver Disease In Hepatitis B Virus Infection: A Case–Control Study

Código QR

Analysis Of Risk Factors For Nonalcoholic Fatty-Liver Disease In Hepatitis B Virus Infection: A Case–Control Study

Ghodsiyeh Azarkar,1 Zahra Doosti,2 Freshteh Osmani,3 Masood Ziaee1 1Infectious Diseases Research Center, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran; 2Infectious Diseases and Tropical medicine Research center, Shahid Beheshti University of Medical Science, Tehran, Iran...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Azarkar G, Doosti Z, Osmani F, Ziaee M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	NAFLD Metabolic Syndrome Liver diseases Hepatitis B Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/36964499e9f04f51b526d92fe54bf631
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Hepatocyte-specific TM6SF2 knockout aggravates hepatic steatosis in mice with nonalcoholic fatty liver disease
por: ZHANG Jie
Publicado: (2021)

Surgical treatment of nonalcoholic fatty liver disease in severely obese patients
por: Vander Naalt SJ, et al.
Publicado: (2014)

Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease
por: Kawanaka M, et al.
Publicado: (2015)

Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks
por: Cheung A, et al.
Publicado: (2021)

Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease
por: LI Pinhua
Publicado: (2021)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome G, et al.
Publicado: (2020)

Challenging hepatitis C-infected liver transplant patients
por: Oliver M, et al.
Publicado: (2016)

GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
por: Shahla Rezaei, et al.
Publicado: (2021)

Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
por: Justine Gillard, et al.
Publicado: (2022)

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
por: Ganguli S, et al.
Publicado: (2019)

Acute Liver Failure due to Hepatitis A Virus
por: Reem Shammout, et al.
Publicado: (2021)

A lipid-rich gestational diet predisposes offspring to nonalcoholic fatty liver disease: a potential sequence of events
por: Hughes AN, et al.
Publicado: (2014)

Autophagy: a new target for nonalcoholic fatty liver disease therapy
por: Mao YQ, et al.
Publicado: (2016)

A serum metabolomics study on the intervention of nonalcoholic fatty liver disease by equicaloric low-carbohydrate high-protein diet combined with aerobic exercise
por: LI Meiying
Publicado: (2021)

Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?
por: Kornerup LS, et al.
Publicado: (2019)

White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in MiceSummary
por: Sadatsugu Sakane, et al.
Publicado: (2021)

Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease
por: Ahmed Z, et al.
Publicado: (2018)

Hepatic sarcoidosis: Clinical characteristics and outcome
por: Christiana Graf, et al.
Publicado: (2021)

Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain
por: Abdulla MA, et al.
Publicado: (2017)

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Behnaz Amernia, et al.
Publicado: (2021)

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease
por: Bradford V, et al.
Publicado: (2013)

Prevalence rate of non-obese fatty liver disease and related influencing factors
por: DENG Jiang
Publicado: (2021)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen M, et al.
Publicado: (2017)

Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study
por: Kawanaka M, et al.
Publicado: (2013)

Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
por: Lau T, et al.
Publicado: (2013)

Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
por: Alia Hadefi, et al.
Publicado: (2021)

Risk factors of nonalcoholic fatty liver disease in lean body mass population: A systematic review and meta‐analysis
por: Shahinul Alam, et al.
Publicado: (2021)

Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program
por: Cervio G, et al.
Publicado: (2011)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Osama Hamdy, et al.
Publicado: (2021)

Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
por: Suad Abdeen, et al.
Publicado: (2011)

PNPLA3 expression and its impact on the liver: current perspectives
por: Bruschi FV, et al.
Publicado: (2017)

E-Selectin-Dependent Inflammation and Lipolysis in Adipose Tissue Exacerbate Steatosis-to-NASH Progression via S100A8/9Summary
por: Robim M. Rodrigues, et al.
Publicado: (2022)

Identifying High-Risk NASH Patients: What We Know so Far
por: Schulz M, et al.
Publicado: (2020)

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
por: Danish FA, et al.
Publicado: (2013)

Reduced steatosis and weight as a result of specific diets or the dietitian themselves
por: Hirsh D. Trivedi, et al.
Publicado: (2021)

Selected biochemical and hematological abnormalities in Nigerians with human immunodeficiency virus and hepatitis C virus coinfection
por: Nwokediuko SC, et al.
Publicado: (2011)

Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications
por: Tawfik AK, et al.
Publicado: (2018)

Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
por: JIANG Yingying
Publicado: (2021)

Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus
por: Bruno S, et al.
Publicado: (2011)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia MD, et al.
Publicado: (2011)